Results 221 to 230 of about 259,206 (307)

Cholinergic Degeneration and Cognitive Function in Early GBA1‐Related Parkinson's Disease

Annals of Neurology, EarlyView.
Objective The phenotype of patients with Parkinson's disease carrying GBA1 variants (GBA‐PD) suggest similarities to symptomatology associated with early cholinergic system degeneration. Therefore, this study aims to investigate the clinical features and the cholinergic innervation pattern in patients with early GBA‐PD versus those without the GBA1 ...
Sofie Slingerland, Sygrid van der Zee, Giulia Carli, Anne C. Slomp, Emile d'Angremont, Jeffrey M. Boertien, Teus van Laar   +6 more
wiley   +1 more source

Impact of scheduled water intake on mild cognitive impairment in patients with orthostatic hypotension. [PDF]

Sci Rep
Wu Y, Feng W, Chen Q, He M, Bai H, Peng R, Liang B, Ma M, Tuo N, Zheng L.   +9 more
europepmc   +1 more source

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease. [PDF]

Front Aging Neurosci
Xu Y, Zhang J, Shen YY, Li WW, Li B, Cheng HP, Zeng GH.   +6 more
europepmc   +1 more source

Self-related thought alterations associated with intrinsic brain dysfunction in mild cognitive impairment. [PDF]

Sci Rep
Tarailis P, Lory K, Unschuld PG, Michel CM, Bréchet L.   +4 more
europepmc   +1 more source

Erratum to “Structural correlates of mild cognitive impairment” [Neurobiology of Aging 25 (2004) 913–924]

, 2004
Henrike Wolf, Anke Hensel, Frithjof Kruggel, Steffi G. Riedel‐Heller, Thomas Arendt, Lars‐Olof Wahlund, Hermann‐Josef Gertz   +6 more
openalex   +1 more source

Comparative Analysis of Phenotypic and Genotypic Differences Between Individuals Affected by Regressive and Non‐Regressive Autism: A Cross‐Sectional Study

Autism Research, EarlyView.
ABSTRACT Development among autistic youth varies widely. A subgroup of children experiences regression, defined as the loss of previously acquired developmental skills. Various genetic and environmental factors have been suggested as potential contributors.
Seyed Hassan Tonekaboni, Alana Iaboni, Brett Trost, Miriam Reuter, Zsuzsa Lindenmaier, Azadeh Kushki, Elizabeth Kelley, Jessica Jones, Muhammed Ayub, Stelios Georgiades, Robert Nicolson, Elim Chan, Andrada Cretu, Jessica Brian, Evdokia Anagnostou   +14 more
wiley   +1 more source

Missed Early Intervention Opportunities for Children With Autism Spectrum Disorder

Autism Research, EarlyView.
ABSTRACT Early intervention (EI) is essential for improving developmental outcomes in children with autism spectrum disorder (ASD). However, participation during the critical neurodevelopmental (0–3 years) period remains a challenge. To identify those factors associated with the participation of preschool children with ASD in EI before age 2, this ...
Daniel E. Lidstone
wiley   +1 more source

Erratum: Patient- and Caregiver-Reported Impact of Symptoms in Alzheimer Disease, Mild Cognitive Impairment, and Dementia. [PDF]

Neurol Clin Pract
Seabury J, Weinstein J, Varma A, Rosero SJ, Engebrecht C, Arky A, Zizzi C, Dilek N, Mathewson A, Salem-Spencer S, Santos EJ, Heatwole CR.   +11 more
europepmc   +1 more source

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

British Journal of Clinical Pharmacology, EarlyView.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins, Miranda Davies, Elizabeth Lynn, Debabrata Roy, Alison Yeomans, Saad A. W. Shakir   +5 more
wiley   +1 more source